Brainstorm Cell Therapeutics (BCLI) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Bristow Group to acquire Berry Aviation for $105 million
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
